Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC reported 21 holdings worth US$1.68B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Bain Capital Life Sciences Investors, LLC reported 21 holdings worth US$1.68B as of Jun 30, 2026. Largest: Kailera Therapeutics, Inc., Heartflow, Inc. and Savara, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 21
- Value as reported
- US$1.68B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Kailera Therapeutics, Inc. | 22.6M | US$498M | 29.6% |
| Heartflow, Inc. | 8.45M | US$248M | 14.7% |
| Savara, Inc. | 17.6M | US$108M | 6.4% |
| Solid Biosciences Inc. | 9.81M | US$98M | 5.8% |
| Olema Pharmaceuticals, Inc. | 7.09M | US$88.6M | 5.3% |
| Hemab Therapeutics Holdings, Inc. | 1.65M | US$60.6M | 3.6% |
| Cabaletta Bio, Inc. | 17.2M | US$53.6M | 3.2% |
| X4 Pharmaceuticals, Inc. | 7.97M | US$37.2M | 2.2% |
| Dianthus Therapeutics, Inc. | 362K | US$35.3M | 2.1% |
| C4 Therapeutics, Inc. | 7.17M | US$33.5M | 2.0% |
| Kyverna Therapeutics, Inc. | 2.88M | US$25.7M | 1.5% |
| Annexon, Inc. | 4.44M | US$25.3M | 1.5% |
| Rapid Micro Biosystems, Inc. | 8.43M | US$14.6M | 0.87% |
| Disc Medicine, Inc. | 141K | US$10.3M | 0.61% |
| Atea Pharmaceuticals, Inc. | 2.08M | US$9.65M | 0.57% |
| Xilio Therapeutics, Inc. | 664K | US$6.36M | 0.38% |
| Upstream Bio, Inc. | 601K | US$4.16M | 0.25% |